NCT00563953View on ClinicalTrials.gov

Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

August 31, 2016

Conditions
Breast Cancer
Interventions
DRUG

Liposomal pegylated doxorubicine

Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.

Trial Locations (8)

25198

Hospital Universitari Arnau de Vilanova, Lleida

28041

Hospital Universitario 12 de Octubre, Madrid

30008

Hospital Universitario Morales Meseguer, Murcia

42301

Hospital Universitario Sant Joan de Reus, Reus

07198

Hospital Son Llàtzer, Palma de Mallorca

08907

Institut Català d'Oncologia, L'Hospitalet de Llobregat

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

SOLTI Breast Cancer Research Group

OTHER

NCT00563953 - Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years | Biotech Hunter | Biotech Hunter